https://www.reuters.com/article/us-health-coronavirus-novavax-idUSKCN2502QT

39 0

(Reuters) - Novavax Inc said on Tuesday its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial, sending the company’s shares up 10%. The company said it could start a large pivotal Phase III trial as soon as late September, and on a conference call added that it could produce 1 billion to 2 billion doses of the vaccine in 2021. Novavax research chief Gregory Glenn told Reuters the late-stage clinical trial could potentially glean enough data to obtain regulatory approvals as early as December. Maryland-based Novavax said its vaccine candidate, NVX-CoV2373, produced higher levels... Tout l'article

5 août

wait